Skip to main content
. 2013 Aug 12;14(10):888–896. doi: 10.4161/cbt.25945

Table 1. Summary of PIK3CA mutational status and their clinicopathological features in BC samples.

Tumor # Age Grade ER PR HER2 Epithelium mutation
Nucleotide: codon (exon)
1 36 II + - 1+ WT
2 48 II - - 3+ WT
3 72 III - - 1+ WT
4 32 II + + 1+ c.3140A > G: p.His1047Arg (20)
5 44 II + - 1+ WT
6 34 III - - 3+ WT
7 62 III + + 3+ WT
8 67 III - - 3+ WT
9 47 III + + 1+ c.3145C > G: p.Gly1049Arg (20)
10 68 III + + 1+ WT
11 40 III + - 3+ WT
12 32 III - - 3+ WT
13 57 II + + 1+ WT
14 31 III - - 1+ WT
15 34 II - - 1+ WT
16 27 II + + 3+ c.3140A > G: p.His1047Arg (20)
17 42 II - - 1+ WT
18 54 III + - 1+ WT
19 66 III + + 3+ WT
20 55 III + + 3+ c.3075C > T: SNP (20)
21 61 II + + 1+ WT
22 50 II + + 1+ WT
23 40 I + - 1+ c.3140A > G: p.His1047Arg (20)
24 60 II + + 1+ c.3140A > G: p.His1047Arg (20)
25 57 III + + 1+ WT
26 42 III - - 3+ c.3075C > T: SNP (20)
c.3140A > G: p.His1047Arg (20)
27 42 III - - 3+ WT
28 54 III + - 1+ c.3140A > G: p.His1047Arg (20)
29 38 III - - 3+ WT
30 32 II + - 1+ WT
31 51 II + + 3+ c.3073A > G: p.Thr1025Ala (20)
32 56 III + + 3+ c.3075C > T: SNP (20)
33 58 II + + 1+ c.3140A > G: p.His1047Arg (20)
34 61 II + + 1+ WT
35 45 I + + 1+ c.3075C > T: SNP (20)
36 40 II - - 1+ WT
37 39 III - - 3+ WT
38 36 II + + 3+ WT
39 55 III - - 1+ WT
40 51 II + - 3+ c.3140A > G: p.His1047Arg (20)
41 40 III - - 3+ c.3140A > G: p.His1047Arg (20)
42 41 III + + 1+ WT
43 46 III - - 1+ WT
44 50 II + + 1+ WT
45 35 III - - 1+ WT
46 51 II + - 1+ WT
47 44 III - - 3+ WT
48 37 III - - 1+ WT
49 45 II + + 1+ WT
50 34 III + + 1+ WT
51 70 I + + 1+ WT
52 47 II - - 3+ WT
53 65 I + + 1+ c.3140A > G: p.His1047Arg (20)
54 36 III - - 3+ WT
55 39 I + + 3+ c.1633G > A: p.Glu545Lys (9)
c.3075C > T: SNP (20)
56 60 II + + 1+ WT
57 63 III + + 1+ c.1633G > A: p.Glu545Lys (9)
58 42 I + + 1+ WT
59 52 II + + 3+ c.3075C > T: SNP (20)
c.3140A > G: p.His1047Arg (20)
60 49 I + + 1+ WT
61 60 I + + 1+ c.3166G > A: p.Asp1056Asn (20)
62 48 II + - 1+ WT
63 56 II + - 3+ WT
64 53 II + + 1+ WT
65 28 DCIS NA NA 1+ c.3140A > T: p.His1047Lys (20)
66 40 II - - 3+ c.1633G > A: p.Glu545Lys (9)
67 45 III - - 3+ WT
68 44 NA NA NA NA c.1633G > A: p.Glu545Lys (9)
69 45 MET - - 1+ c.3075C > T: SNP (20)
70 22 II + + 1+ WT
71 37 III - - 1+ WT
72 45 III - - 3+ c.3140A > G: p.His1047Arg (20)
73 46 II - - 1+ WT
74 49 III + + 3+ WT
75 46 III + - 3+ WT
76 51 III - - 3+ WT
77 53 I + - 1+ c.3140A > G: p.His1047Arg (20)
78 48 III + + 1+ WT
79 39 II + + 3+ WT
80 40 II - - 3+ WT
81 36 II - - 3+ WT

Mutations are shown as nucleotide change followed by amino acid change and the number of exon in parenthesis. Abbreviations: ER, estrogen receptor; PR, progesterone receptor; Her2, human epidermal growth factor receptor 2; WT, wild type; NA, information not available; MET, metastatic; DCIS, ductal carcinoma in situ.